Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CACNA2D1 | P54289 | 12/20 | 0.51 |
| ▸ | CACNB1 | Q02641 | 12/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 11/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.51 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798984 | 0.86 | SERPINE1 (1.00) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL1799860 | 0.85 | SERPINE1 (0.98) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL29351719 | 0.85 | SERPINE1 (0.98) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL26073743 | 0.84 | SERPINE1 (0.77) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL1797947 | 0.84 | SERPINE1 (0.86) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL1799855 | 0.84 | SERPINE1 (0.84) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL1798810 | 0.84 | SERPINE1 (0.84) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL29448186 | 0.84 | SERPINE1 (0.84) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL1798631 | 0.83 | SERPINE1 (0.84) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B | |
| SCHEMBL1799721 | 0.82 | SERPINE1 (0.75) | SERPINE1NPC1CACNA2D1CACNB1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885NPC1 1319/4885CACNA2D1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.